Herbal Treatment for Atrial Fibrillation | Remedies | Herbal Care Products

Atrial Fibrillation Market Research Report: By Type (Paroxysmal and Others), by Treatment (Medications, Non-Surgical Procedures, and Surgical Procedures), by End-User (Hospitals, Electrophysiology Labs, and Ambulatory Surgical Centers)—Forecast till 2027Market HighlightsThe global atrial fibrillation market is estimated to account for USD 11123.8 million and registering a CAGR of ~ 11.2 %.

It is caused by unsystematic electrical activity in the atria of the heart, which causes rapid stimulus of the ventricles, leading to an irregular heartbeat.

According to the Centers for Disease Control and Prevention, Atrial fibrillation (AFib) costs the United States about USD 6 billion annually.

For instance, in January 2017, Abbott completed the acquisition of St. Jude Medical, Inc. St. Jude Medical's strong positions in fast-growing areas such as atrial fibrillation, heart failure, structural heart and chronic pain balance Abbott's leading positions in coronary interventions and mitral valve disease and will further create a strong and diverse product portfolio.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6520Regional AnalysisThe market in the Americas is expected to dominate the global atrial fibrillation market during the forecast period due to the escalation in the adoption of advanced technologies and procedures for the treatment of atrial fibrillation, and well-developed healthcare infrastructure.

According to the Centers for Disease Control and Prevention in 2017, an estimated 2.7–6.1 million people in the United States have atrial fibrillation (AFib).

The European market is expected to be the second-largest due to government funding and support of the healthcare sector.

Atrial fibrillation is a heart symptom where the person has an irregular or fast heart rhythm.

Some of the typical indications of AF are dizziness, confusion, fainting, or tiredness.

There has been promising development in the technological advancement of procedures to treat such condition and are being adopted by the hospitals and clinics.Demand ScenarioThe global atrial fibrillation market was USD 5.16 billion in 2018 and is estimated to reach USD 12.47 billion by 2025 at a CAGR of 13.43% during the forecast periodClick Here to Get Sample Premium Report @ https://www.trendsmarketresearch.com/report/sample/3933Growth by RegionEurope dominates the global market for atrial fibrillation and is likely to continue during the forecast period owing to factors such as rise in the adoption of technologically advanced technologies and advanced healthcare facilities and infrastructure in the region.

The devices are often approved in Europe before entering the US market and the increasing number of catheter ablation procedures contributes towards the growth of the market in this region.

Asia Pacific is expected to have the highest growth rate during the forecast period which can be attributable to factors like its huge patient base and population, its increasing need for atrial fibrillation devices owing to better medical infrastructure and high Chinese & Indian healthcare costs.You can Buy This Report from Here @ https://www.trendsmarketresearch.com/checkout/3933/SingleDrivers vs Constraints The factors that drive the market are AF cases within the elderly population, preference for catheter ablation, and escalating technological developments.

Also various lifestyle illnesses, poor eating habits, and sedentary occupations may also cause a surge in cardiac issues eventually propelling the industry.

However, lack of well-trained physicians and the high cost of treatments are hampering the atrial fibrillation market growth.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1541The report has provided a detailed profile of some of the leading players in the global atrial fibrillation market such as Abbott Laboratories, Biosense Webster, Inc., Medtronic Plc, MicroPort Scientific Corporation, Boston Scientific Corporation, Biotronik SE & Co. KG, CardioFocus, Inc., AtriCure Inc., Koninklijke Philips N.V., and Osypka AG.

The market is also estimated to reach US$ 10,925.1 million revenue by the end of 2026.On the basis of product type, the EP ablation catheters are expected to emerge as the most preferred product in the global atrial fibrillation market.

On the basis of end-user, the market is segmented into electrophysiology labs, hospitals, and ambulatory surgical center.

A maximum number of catheter ablation are performed in Germany.Buy Atrial Fibrillation Market Report –  https://www.transparencymarketresearch.com/checkout.php?rep_id=1541=SRise in the Use of Less Invasive and Advanced Treatment for Atrial FibrillationMajor hospitals and medical centers are using a less invasive procedure known as catheter ablation for treating atrial fibrillation.

It also has facilitated quick recovery than the surgery.

A recent study by the researchers at the Klinikum Coburg and the University of Utah Health also showed that radiofrequency catheter ablation lowered mortality rates in patients suffering from atrial fibrillation.